1. Volume 1, Issue 5, Pages 343-350 (October 2014)
Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data 
Jane Walker, PhD, Christian Holm Hansen, PhD, Paul Martin, MSc, Stefan Symeonides, PhD, Ravi Ramessur, BMBCh, Prof Gordon Murray, PhD, Prof Michael Sharpe, MD 
The Lancet Psychiatry 
Volume 1, Issue 5, Pages (October 2014)
DOI: /S (14)70313-X
Copyright © 2014 Elsevier Ltd Terms and Conditions

2. Figure 1
Study profile
*The patient was taken into their oncology appointment before they were able to complete the Hospital Anxiety and Depression Scale.
The Lancet Psychiatry 2014 1, DOI: ( /S (14)70313-X)
Copyright © 2014 Elsevier Ltd Terms and Conditions

3. Figure 2 Prevalence of major depression in patients with cancer
Error bars show 95% CIs.
The Lancet Psychiatry 2014 1, DOI: ( /S (14)70313-X)
Copyright © 2014 Elsevier Ltd Terms and Conditions

4. Figure 3
Treatments received by outpatients with cancer and major depression
Proportions based on 1538 patients diagnosed with major depression at clinical interview and with complete treatment data. Antidepressant drugs were amitriptyline, citalopram, clomipramine, dosulepin, doxepin, duloxetine, escitalopram, fluoxetine, flupentixol, fluvoxamine, imipramine, lofepramine, mirtazapine, nortriptyline, paroxetine, phenelzine, reboxetine, sertraline, trazodone, trimipramine, venlafaxine.
The Lancet Psychiatry 2014 1, DOI: ( /S (14)70313-X)
Copyright © 2014 Elsevier Ltd Terms and Conditions